
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a leader in the insulin delivery industry with a strong global presence and promising product pipeline. However, risks such as competition and regulatory challenges may impact future growth. Concerns about product design and ease of use may also affect the company's parent company, Medtronic. With a neutral rating and price target of $16, the company's focus on advanced algorithms and partnerships for growth may lead to increased revenue, but uncertainties and potential delays could hinder their success.
Bears say
Minimed Group is facing intense competition in the diabetes market, which may limit its pricing power and compress margins as it strives to offer economically attractive solutions. There is also a risk that payors may limit reimbursement or negotiate for tighter discounts as Minimed's technologies become more widely adopted. Additionally, the company has a history of struggling to meet product development timelines, which could leave it behind faster-moving competitors. With a highly competitive legacy insulin pump market and strong competition in the continuous glucose monitoring space, Minimed faces the challenge of maintaining its market share and competing against larger players with established devices and brand loyalty.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares